Nothing Special   »   [go: up one dir, main page]

AU7175998A - Encapsulated intraluminal stent-graft and methods of making same - Google Patents

Encapsulated intraluminal stent-graft and methods of making same Download PDF

Info

Publication number
AU7175998A
AU7175998A AU71759/98A AU7175998A AU7175998A AU 7175998 A AU7175998 A AU 7175998A AU 71759/98 A AU71759/98 A AU 71759/98A AU 7175998 A AU7175998 A AU 7175998A AU 7175998 A AU7175998 A AU 7175998A
Authority
AU
Australia
Prior art keywords
stent
endoluminal
expanded polytetrafluoroethylene
endoluminal stent
polytetrafluoroethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU71759/98A
Other versions
AU733860B2 (en
Inventor
Christopher E Banas
Tarun J. Edwin
Brendan J. Mccrea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bard Peripheral Vascular Inc
Original Assignee
Bard Peripheral Vascular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/002361 external-priority patent/WO1998033453A2/en
Application filed by Bard Peripheral Vascular Inc filed Critical Bard Peripheral Vascular Inc
Publication of AU7175998A publication Critical patent/AU7175998A/en
Application granted granted Critical
Publication of AU733860B2 publication Critical patent/AU733860B2/en
Assigned to BARD PERIPHERAL VASCULAR, INC. reassignment BARD PERIPHERAL VASCULAR, INC. Request to Amend Deed and Register Assignors: IMPRA, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/962Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve
    • A61F2/966Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • A61F2002/072Encapsulated stents, e.g. wire or whole stent embedded in lining
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/16Materials with shape-memory or superelastic properties

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Description

WO 99/38455 PCT/US98/08994 ENCAPSULATED INTRALUMINAL STENT-GRAFT AND METHODS OF MAKING SAME Cross-Reference to Related Applications 5 This application is a continuation-in-part of co-pending International patent application Serial No. PCT/US95/11817, filed 15 September 1995, which is a continuation-in-part of co pending patent application Serial No. 08/401,871, filed March 10, 1995, both published as International Publication No. WO 96/28115, published September 19, 1996, and co-pending Internatioanl patent application Serial No. PCT/US98/02361, filed February 2, 1998, each of 10 which is expressly incorporated by reference as if fully set forth herein. Background of the Invention The present invention relates generally to implantable intraluminal devices, particularly intraluminal stents. Because of the open lattice found in most intraluminal stents, a primary 15 problem with these types of device is occlusion of the vessel occurring after stent placement. Tissue ingrowth and neointimal hyperplasia significantly reduces the open diameter of the treated lumen over time, requiring additional therapies. The present invention incorporates the use of a biocompatible barrier material that prevents or delays the tissue ingrowth and neointimal hyperplasia, thus maintaining luminal patency for longer periods after initial treatment. The use 20 of expanded polytetrafluoroethylene (ePTFE) as a bio-inert barrier material is well documented. In accordance with certain of its preferred embodiments, the present invention utilizes a radially expandable ePTFE material, such as that described in co-pending International patent application Serial No. PCT/US98/02361, filed February 2, 1998, to partially or fully embed the stent lattice, thereby providing a suitable barrier which improves stent patency. 25 The inventive intraluminal stent-graft device may be implanted either by percutaneous delivery using an appropriate delivery system, a cut-down procedure in which a surgical incision is made and the intraluminal device implanted through the surgical incision, or by laparoscopic or endoscopic or endoscopic delivery. More particularly the present invention relates to shape memory alloy and self-expanding endoluminal stents which are at least partially encapsulated in 30 a substantially monolithic expanded polytetrafluoroethylene ("ePTFE") covering. In accordance with the present invention, an endoluminal stent, which has a reduced diametric dimension for endoluminal delivery and a larger in vivo final diametric diameter, is encapsulated in an ePTFE -1- WO 99/38455 PCT/US98/08994 covering which circumferentially covers both the luminal and abluminal walls along at least a portion of the longitudinal extent of the endoluminal stent. The endoluminal stent is preferably fabricated from a shape memory alloy which exhibits either shape memory or pseudoelastic properties or from an elastic material having an inherent spring tension. In a first embodiment 5 of the invention, the endoluminal stent is encapsulated in the ePTFE covering in the stent's reduced diametric dimension and is balloon expanded in vivo to radially deform the ePTFE covering. The endoluminal stent may be either one which exhibits thermal strain recovery, pseudoelastic stress-strain behavior or elastic behavior at mammalian body temperature. While in its reduced diametric dimension, the ePTFE encapsulating covering integrally constrains the 10 endoluminal stent from exhibiting either thermal strain recovery, pseudoelastic stress-strain behavior or elastic behavior at mammalian body temperature. Radial deformation of the ePTFE covering releases constraining forces acting on the endoluminal stent by the undeformed ePTFE covering and permits the stent to radially expand. In a second embodiment of the invention, an endoluminal stent fabricated of a shape memory alloy is encapsulated in its final diametric 15 dimension and the encapsulated intraluminal stent-graft is manipulated into its reduced diametric dimension and radially expanded in vivo under the influence of a martensite to austenite transformation. In a third embodiment of the present invention, a self-expanding intraluminal stent, fabricated of a material having an inherent spring tension, is encapsulated in its final diametric dimension and manipulated to a reduced diametric dimension and externally 20 constrained for intraluminal delivery. Upon release of the external constraint in vivo the spring tension exerted by the self-expanding stent radially expands both the stent and the ePTFE encapsulating covering to a radially enlarged diameter. In a fourth embodiment of the invention, the endoluminal stent is fabricated from a material having an inherent elastic spring tension and it is encapsulated at a reduced dimension suitable for endoluminal delivery and balloon expanded 25 in vivo to radially deform the ePTFE covering. Shape memory alloys are a group of metallic materials that demonstrate the ability to return to a defined shape or size when subjected to certain thermal or stress conditions. Shape memory alloys are generally capable of being plastically deformed at a relatively low temperature and, upon exposure to a relatively higher temperature, return to the defined shape or size prior 30 to the deformation. Shape memory alloys may be further defined as one that yields a thermoelastic martensite. A shape memory alloy which yields a thermoelastic martensite -2- WO 99/38455 PCT/US98/08994 undergoes a martensitic transformation of a type that permits the alloy to be deformed by a twinning mechanism below the martensitic transformation temperature. The deformation is then reversed when the twinned structure reverts upon heating to the parent austenite phase. The austenite phase occurs when the material is at a low strain state and occurs at a given 5 temperature. The martensite phase may be either temperature induced martensite (TIM) or stress-induced martensite (SIM). When a shape memory material is stressed at a temperature above the start of martensite formation, denoted M, where the austenitic state is initially stable, but below the maximum temperature at which martensite formation can occur, denoted Md, the material first deforms elastically and when a critical stress is reached, it begins to transform by 10 the formation of stress-induced martensite. Depending upon whether the temperature is above or below the start of austenite formation, denoted A,, the behavior when the deforming stress is released differs. If the temperature is below A, the stress-induced martensite is stable, however, if the temperature is above A, the martensite is unstable and transforms back to austenite, with the sample returning to its original shape. U.S. Patent Nos. 5,597,378, 5,067,957 15 and 4,665,906 disclose devices, including endoluminal stents, which are delivered in the stress induced martensite phase of shape memory alloy and return to their pre-programmed shape by removal of the stress and transformation from stress-induced martensite to austenite. Shape memory characteristics may be imparted to a shape memory alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite 20 phase is complete, i.e., a temperature above which the austenite phase is stable. The shape of the metal during this heat treatment is the shape "remembered." The heat treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to transform to the martensite phase. The metal in the martensite phase is then plastically deformed, e.g., to facilitate its delivery into a patient's body. Subsequent heating of the deformed martensite phase 25 to a temperature above the martensite to austenite transformation temperature, e.g., body temperature, causes the deformed martensite phase to transform to the austenite phase and during this phase transformation the metal reverts back to its original shape. The term "shape memory" is used in the art to describe the property of a material to recover a pre-programmed shape after deformation of a shape memory alloy in its martensitic 30 phase and exposing the alloy to a temperature excursion through its austenite transformation temperature, at which temperature the alloy begins to revert to the austenite phase and recover -3- WO 99/38455 PCT/US98/08994 its preprogrammed shape. The term "pseudoelasticity" is used to describe a property of shape memory alloys where the alloy is stressed at a temperature above the transformation temperature of the alloy and stress-induced martensite is formed above the normal martensite formation temperature. Because it has been formed above its normal temperature, stress-induced 5 martensite reverts immediately to undeformed austenite as soon as the stress is removed provided the temperature remains above the transformation temperature. The martensitic transformation that occurs in the shape memory alloys yields a thermoelastic martensite and develops from a high-temperature austenite phase with long-range order. The martensite typically occurs as alternately sheared platelets, which are seen as a 10 herringbone structure when viewed metallographically. The transformation, although a first-order phase change, does not occur at a single temperature but over a range of temperatures that varies with each alloy system. Most of the transformation occurs over a relatively narrow temperature range, although the beginning and end of the transformation during heating or cooling actually extends over a much larger temperature range. The transformation also exhibits hysteresis in that 15 the transformations on heating and on cooling do not overlap. This transformation hysteresis varies with the alloy system. A thermoelastic martensite phase is characterized by having a low energy state and glissile interfaces, which can be driven by small temperature or stress changes. As a consequence of this, and of the constraint due to the loss of symmetry during transformation, a thermoelastic 20 martensite phase is crystallographically reversible. The herringbone structure of athermal martensite essentially consists of twin-related, self-accommodating variants. The shape change among the variants tends to cause them to eliminate each other. As a result, little macroscopic strain is generated. In the case of stress-induced martensite, or when stressing a self-accommodating structure, the variant that can transform and yield the greatest shape change 25 in the direction of the applied stress is stabilized and becomes dominant in the configuration. This process creates a macroscopic strain, which is recoverable as the crystal structure reverts to austenite during reverse transformation. The mechanical properties of shape memory alloys vary greatly over the transformation temperature range. Martensite phase alloys may be deformed to several percent strain at quite 30 a low stress, whereas the austenite phase alloy has much higher yield and flow stresses. Upon -4- WO 99/38455 PCT/US98/08994 heating after removing the stress, the a martensite phase shape memory allow will remember its unstrained shape and revert to its austenite phase. Where a shape memory alloy is exposed to temperature above its transformation temperature, the martensite phase can be stress-induced. Once stress-induced martensite occurs, 5 the alloy immediately strains and exhibits the increasing strain at constant stress behavior. Upon unloading of the strain, however, the shape memory alloy reverts to austenite at a lower stress and shape recovery occurs, not upon the application of heat but upon a reduction of stress. This effect, which causes the material to be extremely elastic, is known as pseudoelasticity and the effect is nonlinear. 10 The present invention preferably utilizes an binary, equiatomic nickel-titanium alloy because of its biocompatibility and that such an alloy exhibits a transformation temperature within the range of physiologically-compatible temperatures. Nickel-titanium alloys exhibit moderate solubility for excess nickel or titanium, as well as most other metallic elements, and also exhibits a ductility comparable to most ordinary alloys. This solubility allows alloying with 15 many of the elements to modify both the mechanical properties and the transformation properties of the system. Excess nickel, in amounts up to about 1%, is the most common alloying addition. Excess nickel strongly depresses the transformation temperature and increases the yield strength of the austenite. Other frequently used elements are iron and chromium (to lower the transformation temperature), and copper (to decrease the hysteresis and lower the deformation 20 stress of the martensite). Because common contaminants such as oxygen and carbon can also shift the transformation temperature and degrade the mechanical properties, it is also desirable to minimize the amount of these elements. As used in this application, the following terms have the following meanings: A Temperature: The temperature at which a shape memory alloy finishes transforming 25 to Austenite upon heating. A, Temperature: The temperature at which a shape memory alloy starts transforming to Austenite upon heating. Austenite: The stronger, higher temperature phase present in NiTi. Hysteresis: The temperature difference between a phase transformation upon heating and 30 cooling. In NiTi alloys, it is generally measured as the difference between AP and MP. -5- WO 99/38455 PCT/US98/08994 MvTemperature: The temperature at which a shape memory alloy finishes transforming to Martensite upon cooling. M, Temperature: The temperature at which a shape memory alloy starts transforming to Martensite upon cooling. 5 Martensite: The more deformable, lower temperature phase present in NiTi. Phase Transformation: The change from one alloy phase to another with a change in temperature, pressure, stress, chemistry, and/or time. Shape Memory: The ability of certain alloys to return to a predetermined shape upon heating via a phase transformation. 10 Pseudoelasticity: The reversible non-linear elastic deformation obtained when austenitic shape memory alloys are strained at a temperature above the A,, but below Md, the maximum temperature at which pseudoelasticity is obtained. Thermoelastic Martensitic Transformation: A diffusionless, thermally reversible phase transformation characterized by a crystal lattice distortion. 15 Summary of the Invention It is a principal objective of the present invention to encapsulate an intraluminal structural support with a substantially monolithic covering of ePTFE. It is a further objective of the present invention to encapsulate a shape memory alloy 20 intraluminal stent with a substantially monolithic covering of ePTFE. It is another object of the present invention to provide a unique library of endoprostheses consisting generally of intraluminal structural supports made of shape memory alloys, which are at least partially encapsulated in a substantially monolithic expanded polytetrafluoroethylene covering, and which exhibit either thermal strain recovery, pseudoelastic stress-strain behavior 25 or elastic behavior at mammalian body temperature. It is a further objective of the present invention to encapsulate a shape memory alloy intraluminal stent at a reduced delivery diametric dimension and balloon expand the ePTFE encapsulated stent-graft to radially deform the ePTFE covering and release the radial constraint exerted by the ePTFE encapsulation on the shape memory stent thereby permitting the shape 30 memory alloy stent to undergo transformation from its radially constrained dimension to an enlarged deployed dimension. -6- WO 99/38455 PCT/US98/08994 It is another objective of the present invention to encapsulate a shape memory alloy intraluminal stent at its enlarged diametric dimension, either with an at least partially unsintered tubular ePTFE extrudate having a diametric dimension comparable to the enlarged diametric dimension of the shape memory alloy intraluminal stent, or with a fully sintered ePTFE tubular 5 member which has been radially expanded to a diametric dimension comparable to the enlarged diametric dimension of the shape memory alloy intraluminal stent and the encapsulated intraluminal stent is then reduced in its diametric dimension for endoluminal delivery. It is yet a further objective of the present invention to encapsulate a self-expanding intraluminal stent, such as a GIANTURCO stent or a pseudoelastic shape memory stent, at a 10 reduced delivery diametric dimension and balloon expand the ePTFE encapsulated stent-graft to radially deform the ePTFE covering and release the radial constraint exerted by the ePTFE encapsulation on the self-expanding stent thereby permitting the self-expanding stent to elastically radially expand to its in vivo diameter. It is another objective of the present invention to encapsulate a self-expanding 15 intraluminal stent at its enlarged diametric dimension, either with an at least partially unsintered tubular ePTFE extrudate having a diametric dimension comparable to the enlarged diametric dimension of the shape memory alloy intraluminal stent, or with a fully sintered ePTFE tubular member which has been radially expanded to a diametric dimension comparable to the enlarged diametric dimension of the self-expanding intraluminal stent and reducing the diametric 20 dimension of the encapsulated stent for endoluminal delivery. It is a still further objective of the present invention to encapsulate at a reduced delivery diametric dimension and balloon expand the ePTFE encapsulated stent-graft to radially deform the ePTFE covering and release the radial constraint exerted by the ePTFE encapsulation on the shape memory stent thereby permitting the stent to radially expand to a larger in vivo diametric 25 dimension either by the shape memory property of the stent material or by elastic spring tension. It is a further objective of the present invention to provide methods of encapsulating shape memory alloy intraluminal stents and self-expanding intraluminal stents, either at their reduced diametric dimension or at their in vivo diametric dimension. It is another objective of the present invention to provide an ePTFE encapsulated 30 intraluminal stent which is encapsulated between luminal and abluminal ePTFE tubular members, -7- WO 99/38455 PCT/US98/08994 where the ePTFE tubular members may be applied to the intraluminal stent in their unsintered, partially sintered or fully sintered state. It is a further objective of the present invention to employ an ePTFE interlayer positioned adjacent either the luminal or the abluminal surface of the intraluminal stent as a bonding 5 adjuvant interlayer between the luminal and abluminal ePTFE tubular members. Brief Description of the Drawings Figure 1 is a perspective view of the ePTFE encapsulated intraluminal stent in accordance with the present invention. 10 Figure 2A is a perspective view of an ePTFE encapsulated intraluminal stent encapsulated at its reduced diametric dimension for intraluminal delivery and balloon assisted expansion in vivo. Figure 2B is a perspective view of the ePTFE encapsulated intraluminal stent of Figure 2A illustrating the ePTFE encapsulated intraluminal stent after balloon assisted expansion. 15 Figure 3 is a side elevational, longitudinal cross-sectional view of the inventive ePTFE encapsulated intraluminal stent encapsulated at its nominal in vivo dimension. Figure 4 is a side elevational, longitudinal cross-sectional view of the inventive ePTFE encapsulated stent of Figure 4, illustrating the ePTFE encapsulated intraluminal stent partially at a reduced intraluminal delivery diameter deformed to a relatively reduced diameter suitable 20 for intraluminal delivery, mounted on a delivery catheter having an axially moveable constraining sheath which constrains the ePTFE encapsulated self-expanding intraluminal stent in its relatively reduced diametric dimension. Figure 5 is a scanning electron micrograph, taken at 300X magnification, of an outer surface of the radially expanded ePTFE material used to encapsulate the balloon assisted radially 25 expandable encapsulated NITINOL stent of the present invention. Figure 6 is a scanning electron micrograph, taken at 300X magnification, of an inner surface of the ePTFE material used to encapsulate the balloon assisted radially expandable encapsulate NITINOL stent of the present invention. Figure 7 is a scanning electron micrograph, taken at 300X magnification, of an outer 30 surface of the ePTFE material used to encapsulate a self-expanding NITINOL or spring tension stent in accordance with the present invention. -8- WO 99/38455 PCT/US98/08994 Figure 8 is a scanning electron micrograph, taken at 300X magnification, of an inner surface of the ePTFE material used to encapsulate a self-expanding NITINOL or spring tension stent of the present invention. Figure 9A is a flow diagram illustrating the inventive process steps to thermomechanically 5 deform a pre-programmed shape memory stent to a reduced diametric dimension for encapsulation or endoluminal delivery. Figure 9B is a flow diagram illustrating the inventive process steps to encapsulate a shape memory alloy stent and a self-expanding stent to make each preferred embodiment of the present invention. 10 Detailed Description of the Preferred Embodiments Figure 1 illustrates the ePTFE encapsulated intraluminal stent 10 of the present invention in a radially enlarged diametric dimension. The inventive ePTFE encapsulated intraluminal stent 10 of the present invention is best illustrated with reference to several preferred embodiments 15 thereof The first preferred embodiment is depicted in Figures 2A-2B and consists generally of an intraluminal stent 12 made of a shape memory alloy which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively smaller diametric dimension
D
1 and is radially expandable in vivo under the influence of a radially outwardly directed force which radially deforms the ePTFE covering 14 and releases the stress exerted on the intraluminal 20 stent 12 while at body temperature to permit the intraluminal stent to undergo deformation to a larger diametric dimension D2 Figures 3-4 generically depict the second, third and fourth preferred embodiments of the present invention an intraluminal stent 20 which is at least partially encapsulated within a substantially monolithic ePTFE covering 14 over at least an entire circumferential portion of the 25 luminal and abluminal surfaces of the intraluminal stent 12. The second, third and fourth preferred embodiments differ from one another based upon the type of intraluminal stent 20 utilized and whether the encapsulated stent device is intended to radially expand in vivo under the influence of the shape memory behavior or elastic spring tension behavior of the intraluminal stent 20 or whether in vivo delivery will be balloon catheter assisted. 30 The second preferred embodiment of the present invention consists generally of an intraluminal stent 20 made of a shape memory alloy which is at least partially encapsulated in a -9- WO 99/38455 PCT/US98/08994 substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension D 2 and in the austenite phase, which is thermomechanically deformed at a temperature induced martensite phase and to a smaller diametric dimension D 1 and constrained by a constraining sheath 22 for endoluminal delivery. Once at the delivery site, the external constraint 22 is 5 removed and the intraluminal stent 20 undergoes martensitic transformation to the austenite state and thermoelastically deforms 24 to its predetermined shape while unfolding or decompressing, without plastically deforming, the ePTFE covering 14 into contact with the luminal tissue (not shown). The third preferred embodiment of the present invention consists generally of a self 10 expanding intraluminal stent 20 made from either an elastic spring material or of a pseudoelastic shape memory material, and is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively small diametric dimension D 2 such that the ePTFE encapsulating covering 14 acts to impart strain upon the intraluminal stent 20 and constrain the intraluminal stent from radial expansion to a relatively larger diametric dimension D, , until intraluminally 15 delivered and the ePTFE encapsulation radially deformed at body temperature to release the strain exerted by the ePTFE covering 14, thereby permitting the self-expanding intraluminal stent 20 to radially deform to a relatively larger diametric dimension. The fourth preferred embodiment of the present invention consists generally of a self expanding intraluminal stent 20 made from either an elastic spring material or a pseudoelastic 20 shape memory material, which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension D 2 such that the ePTFE encapsulating covering 14 restrains the intraluminal stent from further self-expansion. The assembly is then worked, such as by crimping, calendaring, folding, compressing or the like to reduce its diametric dimension to the reduced diametric dimension D 1 suitable for endoluminal 25 delivery and constrained by an external constraining sheath 22. Once positioned at a desired intraluminal site, the constraining sheath 22 is removed to release the constraining force and the intraluminal stent is permitted to elastically expand as denoted by arrows 24, carrying the ePTFE covering 14 into contact with the intraluminal tissue (not shown). As will be illustrated by the following examples and the accompanying process flow 30 diagrams at Figures 9A and 9B, the methods for making each of the foregoing embodiments differ with each preferred embodiment. The difference in the methods is largely due to the -10- WO 99/38455 PCT/US98/08994 selection of intraluminal stent type and whether the intraluminal encapsulated stent is intended for intraluminal delivery by balloon deformation of the ePTFE covering or whether delivery will occur due to the self-expanding property of the intraluminal encapsulated stent and non deformation of the ePTFE covering. 5 First Embodiment In accordance with a first preferred embodiment, illustrated in Figures 2A and 2B, there is provided a balloon expandable encapsulated shape memory alloy intraluminal stent 10. The balloon expandable encapsulated shape memory alloy intraluminal stent 10 consists generally of 10 an endoluminal stent 12 fabricated of a shape memory alloy, preferably one having an A, value at a physiologically acceptable temperature compatible with tissue conservation, such as equiatomic nickel-titanium alloys known as NITINOL. The endoluminal stent 12 is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while the endoluminal stent 12 is in a relatively smaller diametric dimension D 1 . The substantially monolithic ePTFE 15 covering 14 is a continuous integral tubular structure, is free of seams and covers at least part of both the luminal and abluminal surfaces about an entire circumferential section of the endoluminal stent 12 along at least a portion of the longitudinal axis of the intraluminal stent 12. As illustrated in Figures 5 and 6, the substantially monolithic ePTFE covering 14 is characterized by having a node and fibril microstructure where the nodes are oriented generally perpendicular 20 to the longitudinal axis 30 of the stent 12 and the fibrils are oriented generally parallel to the longitudinal axis 30 of the stent 12, with the distance between adjacent nodes being termed the "internodal distance." As more fully described in the parent application, published as International Application No. WO 96/28115, incorporated by reference, the substantially monolithic ePTFE covering 14 is preferably radially deformable at applied pressures less than 25 about six atmospheres, most preferably less than about three atmospheres, due to the deformable nature of the nodes along their longitudinal axis, i.e., radial relative to the substantially monolithic ePTFE covering 14 and perpendicular to the longitudinal axis 30 of the intraluminal stent 12. The encapsulated intraluminal stent 10 is radially expandable in vivo under the influence of a radially outwardly directed force, such as from a balloon catheter, which radially 30 deforms the ePTFE covering to a second relative large diametric dimension, D 2 , to release the constraining stress exerted on the intraluminal stent by the ePTFE covering while the -11- WO 99/38455 PCT/US98/08994 encapsulated intraluminal stent 10 is at body temperature. The simultaneous release of the constraining force exerted by the ePTFE covering permits the intraluminal stent 12 to undergo thermomechanical deformation to a larger diametric dimension. 5 EXAMPLE 1 BALLOON ASSISTED THERMALLY DEPLOYED STENT A balloon assisted encapsulated shape memory alloy stent was constructed by longitudinally slitting about 5 cm of a 60 cm length of a first seamless unsintered expanded PTFE tube having an inner diameter of 3.0 mm. The slit ends were gripped into a fixture allowing the 10 tube to hang vertically. At the opposite end of the tube, a length of wire was attached to assist in threading the tubing through the inner diameter of the stent. The thickness of the ePTFE layer was measured to be about 0.35 mm using a snap gauge. The ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the tube throughout the wall thickness of the ePTFE tube. 15 A 10 X 40 mm shape memory endoluminal stent was placed in a cold, dry environment at approximately -40o C and compressed about a mandrel having an outer diameter of 4.5 mm by mechanically deforming the stent to circumferentially conform to the outer diameter of the mandrel. The compressed stent was then removed from the cold, dry environment and concentrically passed over the outer diameter of the vertically hanging ePTFE tube, passing the 20 wire through the stent lumen to assist in engaging the stent about the abluminal surface of the ePTFE tube without tearing or marring the ePTFE tube. A 3.3 mm diameter mandrel was then slid into the lumen of the ePTFE tube/stent assembly, and the tubing secured to the mandrel using 1/2 inch strips oftetrafluoroethylene (TFE) tape. The assembly was then removed from the vertical hanging fixture. 25 A 60 cm length of a second seamless partially sintered ePTFE tube, having an inner diameter of 4.3 mm, slightly larger inner diameter than the outer diameter of the first ePTFE tube to provide an interference fit between the first and second ePTFE tubes, was slit longitudinally in the same manner as described above, and placed in the vertical hanging fixture. The mandrel bearing the first ePTFE tube and the shape memory stent was then passed into the lumen of the 30 second tube, until the stent was approximately centered on the mandrel. The wall thickness of the second layer was measured as described above, and the thickness was found to be about 0.35 -12- WO 99/38455 PCT/US98/08994 mm. Again, as with the first, inner ePTFE layer, the fibrils were oriented parallel to the longitudinal axis of the tube. The ends of the second tube were also wrapped with strips of TFE tape to secure to the mandrel. The assembly was then placed in a helical winding wrapping machine which tension 5 wraps the assembly with a single overlapping layer of 2 inch TFE tape. The overlap of the winding was about 70%. The tension exerted by the TFE wrapping tape compresses the ePTFE/stent/ePTFE composite structure against the mandrel, thereby causing the layers of ePTFE to come into intimate contact through the interstices of the shape memory stent. The tension wrap was set to exert 1.7 psi pressure circumferentially around the ePTFE/stent/ePTFE 10 and mandrel assembly. The wrapped assembly was placed into a radiant heat furnace, which had been preheated to a 3370 C set point. The assembly remained in the furnace for about 7 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling the TFE helical wrap was unwound from the 15 sample and discarded. The now ePTFE encapsulated stent assembly was then concentrically rotated about the axis of the mandrel to release any adhesion between the inner ePTFE layer and the mandrel. The ePTFE encapsulated stent assembly, still on the mandrel, was placed into a laser trimming fixture to trim excess ePTFE materials away from the proximal and distal ends. After trimming, the trimmed encapsulated stent was removed from the mandrel. 20 Five encapsulated stent samples were prepared in accordance with the foregoing description and were each placed a balloon on a 10 mm by 4 cm PTA balloon dilation catheter. The device was then placed into a temperature controlled water bath maintained at 370 C. The balloon was pressurized using a saline filled inflator, thereby expanding the encapsulated stent. Each encapsulated stent device was radially expanded under the influence of balloon deformation 25 of the ePTFE encapsulating covering with full radial deformation to a 10 mm inner diameter occurring at inflation pressures between 2 and 4 atmospheres. -13- WO 99/38455 PCT/US98/08994 EXAMPLE 2 THIN WALL THERMALLY DEPLOYED STENT The radially expanded encapsulated stents obtained from Example 1 were placed over a 10 mm diameter stainless steel mandrel, and spiral wrapped using /2 inch ePTFE tape as 5 described above. The wrapped assembly was placed again into a radiant heat furnace, which had been preheated to 3370 C set point. The assembly remained in the furnace for about 10 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After air cooling, the ends of the mandrel was engaged in two 10 rings and the TFE helical wrap was unwound from the encapsulated stent samples and discarded. The encapsulated stents were concentrically rotated about the axis of the mandrel to release adhesion between the luminal ePTFE surface of the encapsulated stent and the mandrel. The encapsulated stent was next cooled to about -20 oC in a cold dry environment and allowed to equilibrate for 30 minutes. The cooled encapsulated stent was then rolled between 15 2 plates to successively reduce the encapsulated stent inner diameter to about 3.5 mm, representing a reduction of about 40% from the radially expanded inner diameter of the encapsulated stent. The encapsulated stent at the reduced inner diameter of 3.5 mm was fully inserted into a constraining sheath having an inner diameter of approximately 3.7 mm. The externally constrained encapsulated stent was then removed from the cold 20 environment, and placed into a water bath maintained at a temperature of 370 C. A pusher rod was inserted into the constraining sheath and impinged upon one end of the constrained encapsulated stent. By passing the pusher rod through the constraining sheath, the encapsulated stent was ejected from constraining sheath. As the stent was ejected, it radially dilated from its compressed state, and re-assumed the original fully expanded diametric dimension of about 10 25 mm inner diameter. Second Embodiment The second preferred embodiment of the present invention, depicted in Figures 3-4, consists generally of an intraluminal stent 20 made of a shape memory alloy which is at least 30 partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension D 2 and in the austenite phase, which is thermomechanically deformed to a -14- WO 99/38455 PCT/US98/08994 temperature induced martensite phase and to a smaller diametric dimension D 1 and constrained by constraining sheath 22 for endoluminal delivery. Once at the delivery site, the constraint 22 is removed and the intraluminal stent 20 undergoes martensitic transformation to the austenite state and thermoelastically deforms 24 to its enlarged diametric dimension D 2 while unfolding 5 the ePTFE covering 14 into contact with the luminal tissue (not shown). EXAMPLE 3 THERMALLY SELF-DEPLOYING ENCAPSULATED STENT A thermally deployed encapsulated shape memory alloy stent was constructed by placing 10 a 40 cm length of a first seamless expanded PTFE tube over a 10 mm cylindrical stainless steel mandrel. The inner diameter of the ePTFE tube was of a sufficient size to permit an interference fit with the mandrel. The thickness of the ePTFE layer was measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle. The ePTFE tube has a node-fibril microstructure in which the fibrils are 15 oriented perpendicular to the longitudinal axis of the mandrel throughout the wall thickness of the ePTFE tube. The ends of the ePTFE tube were wrapped with TFE tape to keep the tube from sliding along the mandrel for the next assembly step. A shape memory alloy stent having a nominal inner diameter of about 10 mm and being about 100 mm in length in its enlarged diametric configuration was concentrically placed over the ePTFE covered mandrel at about 220 20 C and positionally centrally along the longitudinal length of the ePTFE tube. The inner diameter of the shape memory stent was toleranced to the outer diameter of the ePTFE tube on the mandrel and engaged about the ePTFE tube without tearing or disturbing the surface of the ePTFE tube. A second seamless ePTFE tube having a wall thickness of 0.20 mm, measured as described above, was concentrically engaged over the stent and the first ePTFE tube by first 25 making diametrically opposed longitudinal slits in one end of the second ePTFE tube and concentrically inserting the mandrel/first ePTFE tube/stent assembly into the lumen of the second tube. Again, as with the first ePTFE tube, the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the second ePTFE tube throughout the wall thickness of the second ePTFE tube. The opposing ends of the 30 second ePTFE tube were secured about the first ePTFE tube and the mandrel by tension wrapping with strips of TFE tape. -15- WO 99/38455 PCT/US98/08994 The entire assembly was then placed in a helical winding tension wrapping machine which tension wrapped the assembly with a single overlapping layer of /V2 inch TFE tape in the same manner as in Example 1 to compress the ePTFE material from the first and second ePTFE tubes into intimate contact with one another through the wall openings of the stent. 5 The wrapped assembly was placed into a radiant heat furnace, which had been preheated to about a 3370 C set point. The assembly remained in the furnace for about 10 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel were engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent assembly and 10 discarded. The encapsulated stent assembly was then circumferentially rotated about the axis of the mandrel to break any adhesion occurring between the luminal ePTFE material and the mandrel. Excess ePTFE material from the proximal and distal ends of the encapsulated stent assembly was then laser trimmed in the manner described in Example 1 and the encapsulated stent assembly was removed from the mandrel. 15 The encapsulated stent was then cooled to about -20 0 C in a cold dry environment and allowed to equilibrate for 30 minutes. The encapsulated stent was then flattened between 2 plates to bring diametrically opposed luminal wall surfaces of the encapsulated stent into contact with one another, thereby creating a flat structure without an inner lumen. The encapsulated stent was then folded over itself along its longitudinal axis once, and then again for a total of one flattening 20 operation and two folding operations. Thus, the diameter of the embedded stent was reduced about 60% from it original post encapsulated diameter. While still in the cold, dry environment, the device was fully inserted into a constraining sheath with an internal diameter of approximately 4.7 mm. The folded and sheathed stent was then removed from the cold environment, and placed 25 into a water bath maintained at a temperature of 37 0 C. A pusher was inserted into the lumen of the constraining sheath and the encapsulated stent was ejected from the constraining sheath as described above in Example 2. As the stent was ejected, it unfolded from its flattened and folded state, and re-assumed the original tubular diametric configuration having a nominal inner diameter of 10 mm. 30 -16- WO 99/38455 PCT/US98/08994 Third Embodiment The third preferred embodiment of the present invention, depicted in Figures 2A-2B, and consists generally of self-expanding intraluminal stent 10 made from either an elastic spring material or of a pseudoelastic shape memory material, and is at least partially encapsulated in a 5 substantially monolithic ePTFE covering 14 while in a relatively small diametric dimension D 1 such that the ePTFE encapsulating covering 14 acts to impart strain upon the intraluminal stent 10 and constrain the intraluminal stent 10 from radial expansion to a relatively larger diametric dimension D 2 .. Until it is intraluminally delivered and the ePTFE encapsulation 14 radially deformed at body temperature to release the strain exerted by the ePTFE covering 14 the self 10 expanding intraluminal stent 10 cannot radially deform to a relatively larger diametric dimension
D
2 • EXAMPLE 4 ELASTIC SPRING BALLOON DEPLOYED ENCAPSULATED STENT 15 An encapsulated elastically self-expanding stainless steel stent was constructed by placing a 30 cm length of seamless unsintered ePTFE tube over a 3.3 mm cylindrical stainless steel mandrel. The inner diameter of the ePTFE tube was toleranced to provide a slight interference fit to the mandrel. The thickness of the ePTFE layer was measured to be about 0.35 mm by direct measurement of seamless tube wall using a snap gauge. The ePTFE tube has a node-fibril 20 microstructure in which the fibrils are oriented parallel to the longitudinal axis ePTFE tube throughout the wall thickness of the ePTFE tube. The ends of the ePTFE tube were wrapped with strips of TFE tape to retain the position of the ePTFE tube on the mandrel for the next assembly step. A second seamless sintered ePTFE tube was concentrically engaged over the first ePTFE tube by first longitudinally slitting opposing ends of the ends of the second tube, then 25 inserting the mandrel and first ePTFE tube into the lumen of the second ePTFE tube. One end of the second ePTFE was wrapped with strips of /2 inch TFE tape to secure it to the first ePTFE tube and the mandrel. The wall thickness of the second layer was measured as described above, and the thickness was found to be about 0.35 mm. As with the first ePTFE tube, the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the 30 longitudinal axis of the ePTFE tube. An elastic spring stainless steel stent having a nominal inner diameter of about 15 mm and a length of about 24 mm in its enlarged diametric configuration was inserted into a constraining sheath to reduce the inner diameter to about 4.0 mm. A small length of the stent is left exposed -17- WO 99/38455 PCT/US98/08994 from one end of the constraining sheath. The constraining sheath containing the radially constrained stent was inserted over the mandrel, and forced between the first and second ePTFE tubes such that it was positioned intermediate to the first and second ePTFE tubes. The exposed end of the stent was then frictionally engaged through the second ePTFE tube wall and the 5 constraining sheath retracted, leaving the stent positioned between the first and second ePTFE tubes. The unsecured end of the second ePTFE tube was then secured to the first ePTFE tube and the mandrel with strips of 2 inch TFE tape. The assembly was then placed in a helical winding machine to tension wrap a single overlapping layer of /2 inch TFE tape, and sintered in a radiant heat furnace, cooled, the TFE 10 tape unwrapped and the excess ePTFE laser trimmed as described in Example 1 above. The resulting encapsulated stent was placed over the balloon on a 12 mm by 4 cm PTA balloon dilation catheter. The device was then placed into a temperature controlled water bath maintained at 45 C. The balloon was pressurized using a saline filled inflator which radially deformed the ePTFE encapsulation and permitted radial expansion of the elastically self 15 expanding stent. The encapsulated stent fully radially expanded to a 12 mm inner diameter at an applied pressure of 2.5 atmospheres. Fourth Embodiment The fourth preferred embodiment of the present invention, also representatively depicted 20 in Figures 3-4, consists generally of a self-expanding intraluminal stent 20 made from either an elastic spring material or a pseudoelastic shape memory material, which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric D 2 dimension such that the ePTFE encapsulating covering 14 acts as to restrain the intraluminal stent 20 from further self-expansion. The encapsulated assembly is then worked, 25 such as by crimping, calendaring, folding, or the like, to its reduced diametric dimension D 1 to achieve a profile suitable for endoluminal delivery and the assembly is then constrained by an external constraining sheath 22. Once positioned at a desired intraluminal site, the constraining sheath 22 is removed to release the constraining force and the intraluminal stent 20 is permitted to elastically expand 24, carrying the ePTFE covering 14 into contact with the intraluminal tissue 30 (Not shown). -18- WO 99/38455 PCT/US98/08994 EXAMPLE 5 STRESS-INDUCED MARTENSITE SELF-DEPLOYING ENCAPSULATED STENT A self deploying encapsulated shape memory alloy stent is constructed by placing a 40 5 cm length of seamless expanded PTFE tube over a 10 mm cylindrical stainless steel mandrel. The inner diameter of the ePTFE tube is closely toleranced to provide a slight interference fit to the mandrel. The thickness of the ePTFE layer is measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle. The tubing is constructed such that the fibrils are oriented perpendicular to the longitudinal axis 10 of the mandrel. The ends of the seamless tube are wrapped with strips of TFE tape to keep the tube from sliding along the mandrel for the next assembly step. A shape memory alloy stent about 10 mm inner diameter by 100 mm in length in its enlarged diametric configuration is placed over the ePTFE covered mandrel at about 220 C and centered over the ePTFE layer. The inner diameter of the shape memory stent is closely toleranced to the outer diameter of the ePTFE 15 covered mandrel. A second tube of seamless expanded PTFE is placed over the stent by slitting the ends of the second tube, and inserting the mandrel, ePTFE tube, and stent assembly into the second tube. The wall thickness of the second layer is measured as described above, and the thickness is found to be about 0.20 mm. Again, as with the first, inner ePTFE layer, the fibrils are oriented perpendicular to the longitudinal axis of the mandrel. The ends of the second tube 20 are also wrapped with strips of TFE tape. The assembly is then placed in a helical winding machine which wraps the assembly with a single overlapping layer of 1/2 inch TFE tape. The overlap of the winding was about 70%. The wrapping material compresses the ePTFE/Stent/ePTFE composite structure against the mandrel, causing the layers of ePTFE to come into intimate contact through the interstices of the shape 25 memory stent. The wrapped assembly is placed into a radiant heat furnace, which is preheated to a 3370 C set point. The assembly remains in the furnace for about 10 minutes, and removed. The heated assembly is allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel are engaged in two rings, allowing the TFE 30 helical wrap to be unwound from the sample and discarded. The ePTFE/Stent assembly is then rotated about the axis of the mandrel to break the grip of the inner ePTFE layer to the mandrel. The stent sample, while still on the mandrel, is placed into a fixture to allow for laser trimming of the ePTFE materials away from the embedded stent. Trimming operation is performed on -19- WO 99/38455 PCT/US98/08994 both ends of the device. After trimming, the embedded and trimming stent was removed from the mandrel. The encapsulated stent is then rolled between 2 plates, reducing the diameter of the stent to about 3.5 mm. Thus the diameter of the embedded stent is reduced about 40% from its 5 original post encapsulated diameter. While in the compressed state, the device is fully inserted into a constraining sheath with an internal bore of approximately 3.7 mm. The constrained stent is placed into a water bath maintained at a temperature of 370 C. A pusher was inserted into the bore of the sheath, and the stent ejected from the constraining sheath. As the stent was ejected, it unfurled from its flattened and folded state, and re-assumed 10 the original post encapsulation tubular diametric configuration. Fifth Embodiment In accordance with a fifth preferred embodiment of the inventive encapsulated stent, an at least partially unsintered tubular interlayer is interdisposed between the inner and outer ePTFE 15 layers and adjacent the intraluminal stent along at least a longitudinal extent thereof The interlayer member may consist of a single tubular member which extends along at least a portion of the longitudinal axis of the intraluminal stent. Alternatively, the interlayer member may consist of a plurality of ring-like members positioned along the longitudinal axis of the intraluminal stent and in spaced-apart relationship from one and other. The interlayer member is may be preferably 20 employed either I) where at least one of the inner and outer ePTFE tubular members of the inventive encapsulated intraluminal stent is fully sintered to formation of a monolithic joining of the inner and outer ePTFE tubular members, and/or ii) to serve as a barrier between a radiopaque marker and the intraluminal stent to insulate against galvanic corrosion resulting from contact of metal atoms in a radiopaque marker and metal in an intraluminal stent. 25 The interlayer member may be employed with any type of intraluminal stent, i.e., a shape memory alloy which behaves in either a thermoelastic or pseudoelastic manner, with a self expanding stent in which radial expansion is a spring tension mediated event, or with a balloon expandable stent. 30 EXAMPLE 6 THERMALLY SELF-DEPLOYING ENCAPSULATED STENT A thermally deployed encapsulated shape memory alloy stent was constructed by placing a 40 cm length of a first sintered seamless expanded PTFE tube over a 10 mm cylindrical -20- WO 99/38455 PCT/US98/08994 stainless steel mandrel. The inner diameter of the ePTFE tube was of a sufficient size to permit an interference fit with the mandrel. The thickness of the ePTFE layer was measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle. The ePTFE tube has a node-fibril microstructure in which the 5 fibrils are oriented parallel to the longitudinal axis of the mandrel throughout the wall thickness of the ePTFE tube. The ends of the ePTFE tube were wrapped with TFE tape to keep the tube from sliding along the mandrel for the next assembly step. A shape memory alloy stent having a nominal inner diameter of about 10 mm and being about 100 mm in length in its enlarged diametric configuration was concentrically placed over the ePTFE covered mandrel at about 220 10 C and positionally centrally along the longitudinal length of the ePTFE tube. The inner diameter of the shape memory stent was toleranced to the outer diameter of the ePTFE tube on the mandrel and engaged about the ePTFE tube without tearing or disturbing the surface of the ePTFE tube. A pair of unsintered ePTFE rings, prepared by wrapping unsintered ePTFE films 15 concentrically about each of the opposing ends of the shape memory alloy stent and the first sintered ePTFE tube, such that the node and fibril microstructure of the unsintered ePTFE rings had a fibril orientation perpendicular to the fiber orientation of the first ePTFE tube and the longitudinal axis of the stent. A second sintered seamless ePTFE tube having a wall thickness of 0.20 mm, measured 20 as described above, was concentrically engaged over the entire length of the stent, the pair of unsintered ePTFE rings and the first ePTFE tube by first making diametrically opposed longitudinal slits in one end of the second ePTFE tube and concentrically inserting the mandrel/first ePTFE tube/stent assembly into the lumen of the second tube. Again, as with the first ePTFE tube, the second ePTFE tube has a node-fibril microstructure in which the fibrils are 25 oriented parallel to the longitudinal axis of the second ePTFE tube throughout the wall thickness of the second ePTFE tube. The opposing ends of the second ePTFE tube were secured about the first ePTFE tube and the mandrel by tension wrapping with strips of TFE tape. The entire assembly was then placed in a helical winding tension wrapping machine which tension wrapped the assembly with a single overlapping layer of /2 inch TFE tape in the same 30 manner as in Example 1 to compress the ePTFE material from the first and second ePTFE tubes into intimate contact with one another through the wall openings of the stent. The wrapped assembly was placed into a radiant heat furnace, which had been preheated to about a 337' C set point. The assembly remained in the furnace for about 10 minutes, and was -21- WO 99/38455 PCT/US98/08994 removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel were engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent assembly and discarded. The encapsulated stent assembly was then circumferentially rotated about the axis of 5 the mandrel to break any adhesion occurring between the luminal ePTFE material and the mandrel. Excess ePTFE material from the proximal and distal ends of the encapsulated stent assembly was then laser trimmed in the manner described in Example 1 and the encapsulated stent assembly was removed from the mandrel. The encapsulated stent was then cooled to about -20oC in a cold dry environment and 10 allowed to equilibrate for 30 minutes. The encapsulated stent was then flattened between 2 plates to bring diametrically opposed luminal wall surfaces of the encapsulated stent into contact with one another, thereby creating a flat structure without an inner lumen. The encapsulated stent was then folded over itself along its longitudinal axis once, and then again for a total of one flattening operation and two folding operations. Thus, the diameter of the embedded stent was reduced 15 about 60% from it original post encapsulated diameter. While still in the cold, dry environment, the device was fully inserted into a constraining sheath with an internal diameter of approximately 4.7 mm. The folded and sheathed stent was then removed from the cold environment, and placed into a water bath maintained at a temperature of 37 C. A pusher was inserted into the lumen of 20 the constraining sheath and the encapsulated stent was ejected from the constraining sheath as described above in Example 2. As the stent was ejected, it unfolded from its flattened and folded state, and re-assumed the original tubular diametric configuration having a nominal inner diameter of 10 mm. While the interlayer member employed in the foregoing Example 6 was a sheet of 25 unsintered ePTFE material, it will also be appreciated that tubular or ring-like unsintered ePTFE members may be employed. Where the interlayer member is a tubular or ring-like unsintered ePTFE member, the interlayer member will preferably have a node and fibril microstructure in which the fibril orientation of the interlayer member is parallel to the longitudinal axis of the interlayer member and parallel with the fibril orientation of the inner and outer ePTFE tubular 30 members which the interlayer member is interdisposed between. This co-parallel arrangement of the fibril orientations of the interlayer member and the inner and outer ePTFE tubular members permits the resulting encapsulated stent device to be further radially expanded by balloon expansion in order to further model the in vivo profile to the receiving anatomical -22- WO 99/38455 PCT/US98/08994 structure at radial expansion pressures comparable to that of the balloon assisted encapsulated stent embodiments described above. Where a thermoelastic transformation of a shape memory intraluminal stent is desired, care must be taken to 1) avoid imparting a secondary shape memory to the shape memory alloy 5 during sintering of the ePTFE encapsulating covering, 2) avoid inducing stress-induced martensite formation during thermomechanical forming for either encapsulation or mounting onto a delivery catheter, and 3) avoid inducing non-recoverable strains by exceeding the strain limit of the shape memory alloy material used. Where the elastic behavior of a stent made of either a pseudoelastic shape memory alloy or a spring tension material, care must be taken to 10 avoid plastically deforming the stent which would deleteriously effect the elastic deformation property of the intraluminal stent during intraluminal delivery. Finally, where the pseudoelastic behavior of an intraluminal stent made of a shape memory material is to be utilized in the encapsulated intraluminal stent, care must be taken to maintain the temperature of the shape memory alloy above A,, but below Md during either the process of encapsulating the stent at a 15 reduced diameter, and before sintering, for balloon expansion in vivo or during deformation of the encapsulated stent to a reduced delivery diameter for loading onto a delivery catheter. In this manner, the stress-induced martensite phase will be induced in the shape memory alloy during deformation of the stent to a diametric dimension suitable for endoluminal delivery and maintained so that when the encapsulated stent, in the stress-induced martensite state is delivered 20 and either the ePTFE constraint or the constraining sheath is relieved, the strain is released and the stent, in the stress-induced martensite phase is permitted to transform to austenite and the stent to elastically deform to its pre-programed diametric dimension. The methods described in the foregoing Examples are summarized in Figures 9A-9B, which are process flow diagrams setting forth the fundamental method steps of the methods to 25 make each of the above-described preferred embodiments. Where a shape memory intraluminal stent is to be encapsulated in an ePTFE covering, and thermoelastic transformation of the shape memory stent is desired, either in a balloon assisted expandable encapsulated stent embodiment or in a self-expanding encapsulated stent embodiment, the thermoelastic deformation of the shape memory stent from its enlarged diametric dimension D 2 to its reduced diametric dimension D 1 30 may be accomplished in accordance with the method 40 set forth in Figure 9A. Thermoelastic deformation method 40 entails first providing an shape memory alloy intraluminal stent having a predetermined shape memory configuration 42. The intraluminal stent is then exposed to a temperature below the martensite transformation temperature M,, of the shape memory alloy 44 -23- WO 99/38455 PCT/US98/08994 and allowed to equilibrate at the sub-martensite transformation temperature M,. While still below the M, temperature, the stent is mechanically deformed to reduce its diameter from the enlarged diametric dimension D 2 to a reduced diametric dimension D, suitable for endoluminal delivery. The stent at its reduced diametric dimension is now at a dimensional state suitable for 5 encapsulation at its reduced diametric dimension D 1 . The encapsulation method 60 is more fully set forth in Figure 9B, and is applicable for either a shape memory alloy intraluminal stent which is to be encapsulated either at its reduced diametric dimension D 1 or at its enlarged diametric dimension D 2 , as well as for a self-expanding stent which radially expands due to inherent spring tension in the stent. A luminal ePTFE tube 10 62 is concentrically engaged upon a mandrel 64 and secured to the mandrel. Either a shape memory stent or a self-expanding stent is selected at step 66. If a shape memory stent is selected 70, the shape memory stent 52 is engaged over the luminal ePTFE tube at step 54 while maintaining the stent at a temperature below As to prevent the stent from radially expanding. If a self-expanding stent is selected 68, an abluminal ePTFE tube is concentrically engaged over 15 the luminal ePTFE tube and the self-expanding stent 80 interdisposed between the luminal and abluminal ePTFE tubes and secured there between 78. Where a shape memory alloy intraluminal stent is employed 74, the abluminal ePTFE tube is concentrically engaged over the stent. Once the stent is positioned intermediate between the luminal and abluminal ePTFE tubes, the entire assembly is then wrapped with TFE tape 82 to exert a circumferential pressure about the entire 20 circumference of both the luminal and abluminal ePTFE tubes and the stent, causing the ePTFE tubes to be motivated into intimate contact with one and other through the interstices of the stent. The entire wrapped assembly is then sintered 84 and excess ePTFE overlaying ends of the stent may be trimmed 86. Once trimmed, the encapsulated stent is then prepared for mounting onto a delivery 25 catheter 88, either by mounting the encapsulated stent in its reduced diametric dimension D 1 onto a balloon catheter for balloon-assisted delivery, or by thermomechanical deformation from the enlarged diametric dimension D 2 to the reduced diametric dimension D, following the method steps of thermomechanical deformation 40 or formation of stress-induced martensite for pseudoelastic recovery by crimping, folding or otherwise reducing the encapsulated stent to its 30 reduced diametric dimension D 1 , mounting onto a delivery catheter and applying an external constraining sheath concentrically over the encapsulated stent. Those skilled in the art will understand and appreciate that while the present invention has been described with reference to its preferred embodiments and the examples contained -24- WO 99/38455 PCT/US98/08994 herein, certain variations in material composition, shape memory alloy constitution, stent and ePTFE dimensional size and configuration, temperatures, times and other operational and environmental conditions may be made without departing from the scope of the present invention which is limited only by the claims appended hereto. For example, one skilled in the art will 5 understand and appreciate from the foregoing that the methods for making each of the foregoing embodiments differs with each preferred embodiment. These differences in the methods are largely due to the selection of intraluminal stent type and whether the intraluminal encapsulated stent is intended for intraluminal delivery by balloon expansion or whether delivery will occur due to the self-expanding property of the intraluminal encapsulated stent. 10 -25-

Claims (30)

1. An endoluminal prosthesis, comprising: an endoluminal stent made of a shape memory material, the endoluminal stent having an at least substantially austenite dimensional state whereby the endoluminal stent 5 assumes a generally tubular conformation defining a central longitudinal lumen delimited by walls of the endoluminal stent, the walls having luminal and abluminal surfaces thereof, and a monolithic expanded polytetrafluoroethylene layer forming a continuous circumferential covering over at least a portion of the longitudinal axis of each of the luminal and abluminal surfaces of the endoluminal stent walls circumferentially enclosing at least a portion 10 of the central longitudinal lumen of the endoluminal stent, the expanded polytetrafluoroethylene layer having a node and fibril microstructure wherein the fibrils have a generally uniaxial orientation throughout the monolithic expanded polytetrafluoroethylene layer.
2. The endoluminal prosthesis according to Claim 1, wherein the shape memory 15 stent further comprises a nickel-titanium alloy.
3. The endoluminal prosthesis according to Claim 2, wherein the nickel-titanium alloy further comprises an alloy consisting essentially of nickel present at about 50 at. %, titanium present at about 50 at. %. 20
4. The endoluminal prosthesis according to Claim 1, wherein the monolithic expanded polytetrafluoroethylene layer further comprises a luminal and an abluminal layer of expanded polytetrafluoroethylene tubular material intimately joined to one another through the walls of the endoluminal stent. 25
5. The endoluminal prosthesis according to Claim 1, wherein the monolithic expanded polytetrafluoroethylene layer encapsulates the endoluminal stent in a reduced diametric dimension suitable for endoluminal delivery. 30
6. The endoluminal prosthesis according to Claim 4, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise radially pre-expanded microporous polytetrafluoroethylene tubular members and the endoluminal stent -26- WO 99/38455 PCT/US98/08994 made of a shape memory material is substantially encapsulated at an enlarged diametric dimension.
7. The endoluminal prosthesis according to Claim 4, wherein the luminal and 5 abluminal layers of expanded polytetrafluoroethylene material further comprise expanded polytetrafluoroethylene tubular members extruded at a diametric dimension sufficient to substantially encapsulate the endoluminal stent at its austenite dimensional state.
8. The endoluminal prosthesis according to any of claims 1 to 7, wherein the shape 10 memory material comprising the endoluminal stent further comprises a pseudoelastic shape memory alloy.
9. An endoluminal prosthesis, comprising: an endoluminal stent made of a material having an elastic spring tension having a 15 generally tubular conformation defining a central longitudinal lumen delimited by walls of the endoluminal stent, the walls having luminal and abluminal surfaces thereof, the endoluminal stent having a first dimensional state whereby the endoluminal stent is radially constrained for endoluminal delivery into a body and a second dimensional state whereby the elastic spring tension is released and the endoluminal stent elastically deforms into contact with endoluminal 20 tissue; and a monolithic expanded polytetrafluoroethylene layer forming a continuous circumferential covering over each of the luminal and abluminal surfaces of the endoluminal stent walls circumferentially enclosing at least a portion of the central longitudinal lumen of the endoluminal stent. 25
10. The endoluminal prosthesis according to Claim 9, wherein the monolithic expanded polytetrafluoroethylene layer further comprises a luminal and an abluminal layer of expanded polytetrafluoroethylene tubular material intimately joined to one another through the walls of the endoluminal stent. 30
11. The endoluminal prosthesis according to Claim 10, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise radially pre-expanded microporous polytetrafluoroethylene tubular members. -27- WO 99/38455 PCT/US98/08994
12. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene tubular material further comprise polytetrafluoroethylene tubular members extruded at a diametric dimension sufficient to 5 substantially encapsulate the endoluminal stent at an enlarged diametric dimension.
13. The endoluminal prosthesis according to Claim 12, wherein the abluminal polytetrafluoroethylene tubular member is extruded at a diametric dimension greater than that required to encapsulate the abluminal wall of the endoluminal stent. 10
14. The endoluminal prosthesis according to Claim 10, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise microporous polytetrafluoroethylene tubular members radially expandable under the influence of a radially outwardly directed pressure less than about six atmospheres. 15
15. The endoluminal prosthesis according to Claim 10, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise microporous polytetrafluoroethylene tubular members radially expandable under the influence of a radially outwardly directed pressure less than about five atmospheres. 20
16. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise microporous polytetrafluoroethylene tubular members radially expandable under the influence of a radially outwardly directed pressure less than about four atmospheres. 25
17. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise radially expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied 30 from the central longitudinal lumen of the endoluminal prosthesis less than about six atmospheres. -28- WO 99/38455 PCT/US98/08994
18. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise radially expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied 5 from the central longitudinal lumen of the endoluminal prosthesis less than about five atmospheres.
19. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise radially 10 expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied from the central longitudinal lumen of the endoluminal prosthesis less than about 4.5 atmospheres. 15 20. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene further comprise radially expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied from the central longitudinal lumen of the endoluminal prosthesis less than about 3.0 atmospheres.
20
21. A method for making an encapsulated stent-graft, comprising the steps of: a. concentrically engaging an endoluminal stent in a first diametric dimension about a first tubular expanded polytetrafluoroethylene member having a node and fibril microstructure in which the fibrils are oriented 25 substantially parallel to the longitudinal axis of the tubular expanded polytetrafluoroethylene member; b. concentrically engaging a second tubular expanded polytetrafluoroethylene member having a node and fibril microstructure in which the fibrils are oriented substantially parallel to the longitudinal 30 axis of the second tubular expanded polytetrafluoroethylene member, about the endoluminal stent and the first tubular expanded polytetrafluoroethylene member; -29- WO 99/38455 PCT/US98/08994 c. applying a circumferential pressure about the first and second tubular expanded polytetrafluoroethylene members and the endoluminal stent interdisposed there between; and d. exposing the first and second tubular expanded polytetrafluoroethylene 5 members and the endoluminal stent interdisposed there between stent in its enlarged diametric state to a temperature above the crystalline melt point of polytetrafluoroethylene for a period of time sufficient to monolithically join the layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially 10 homogeneous layer of expanded polytetrafluoroethylene.
22. The method of Claim 21, where the step (a) further comprises the steps of: a. providing an endoluminal stent made of a shape memory material having a pre-defined austenite tubular dimensional state and cooling the 15 endoluminal stent to a temperature below the martensite transformation temperature of the shape memory alloy; and b. deforming the endoluminal stent at a temperature below the martensite transformation temperature to a reduced diametric dimension suitable for endoluminal delivery thereof for engagement upon the first tubular 20 polytetrafluoroethylene member.
23. The method of Claim 21, wherein the step (a) further comprises the steps of: a. providing a self-expanding endoluminal stent made of a material having an inherent spring tension; and 25 b. deforming the endoluminal stent to a reduced diametric dimension suitable for endoluminal delivery thereof for engagement upon the first tubular polytetrafluoroethylene member.
24. The method of Claim 21, wherein the step (a) further comprises the steps of 30 providing an endoluminal stent made of a shape memory material having a pre-defined austenite tubular dimensional state and step (b) is performed while the endoluminal stent is at the pre defined austenite tubular dimensional state. -30- WO 99/38455 PCT/US98/08994
25. The method of Claim 21, wherein the step (a) further comprises the steps of providing a self-expanding endoluminal stent made of a material having an inherent spring tension and the step (b) is performed while the endoluminal stent is at a radially unstrained dimensional state. 5
26. A method for making a stent-graft, comprising the steps of a. transforming a shape memory endoluminal stent from a substantially austenite phase to a temperature-induced martensite phase; b. reducing the diametric dimension of the endoluminal stent in its 10 temperature-induce martensite phase from a larger diametric dimension to a reduced diametric dimension; c. constraining the endoluminal stent in a temperature-induced martensite phase and in its reduced diametric dimension with a substantially monolithic covering of expanded polytetrafluoroethylene 15 circumferentially covering at least a portion of the longitudinal extent of the endoluminal stent, the substantially monolithic covering of expanded polytetrafluoroethylene being radially deformable to release constraining force exerted on the endoluminal stent. 20
27. A method for making an encapsulated stent-graft, comprising the steps of: a. cooling an endoluminal stent made of a shape memory material and having a pre-determined austenite tubular dimensional state to a temperature below the martensite transformation temperature of the shape memory alloy; 25 b. deforming the endoluminal stent at a temperature below M to reduce the diametric dimension of the endoluminal stent to a diameter suitable for endoluminal delivery thereof, the deformation being performed substantially without plastic deformation of the endoluminal stent; c. concentrically engaging the deformed endoluminal stent in its deformed 30 martensite state about a first layer of longitudinally expanded polytetrafluoroethylene; -31- WO 99/38455 PCT/US98/08994 d. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the deformed endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene; e. applying a circumferential pressure about the first and second layers of 5 longitudinally expanded polytetrafluoroethylene and the deformed endoluminal stent; and f exposing the first and second layers of longitudinally expanded polytetrafluoroethylene and endoluminal stent in its reduced diametric state to a temperature above the crystalline melt point of the 10 polytetrafluoroethylene for a period of time sufficient to monolithically join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene. 15
28. A method for making an encapsulated stent-graft, comprising the steps of: a. an endoluminal stent made of a pseudoelastic material and having a pre determined austenite tubular dimensional state at a temperature above the martensite transformation temperature of the shape memory alloy; b. deforming the endoluminal stent at a temperature above Af, but below Md 20 to reduce the diametric dimension of the endoluminal stent to a diameter suitable for endoluminal delivery thereof, the deformation being performed substantially without plastic deformation of the endoluminal stent; c. concentrically engaging the deformed endoluminal stent in its reduced 25 diametric state about a first layer of longitudinally expanded polytetrafluoroethylene; d. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the deformed endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene; 30 e. applying a circumferential pressure about the first and second layers of longitudinally expanded polytetrafluoroethylene and the endoluminal stent; and -32- WO 99/38455 PCT/US98/08994 f exposing the first and second layers of longitudinally expanded polytetrafluoroethylene and endoluminal stent in its reduced diametric state to a temperature above the crystalline melt point of the polytetrafluoroethylene for a period of time sufficient to monolithically 5 join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene.
29. A method for making an encapsulated stent-graft, comprising the steps of: 10 a. concentrically engaging the endoluminal stent in its enlarged state about a first layer of longitudinally expanded polytetrafluoroethylene; b. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the enlarged endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene; 15 c. applying a circumferential pressure about the layers of longitudinally expanded polytetrafluoroethylene and the endoluminal stent; and d. exposing the layers of longitudinally expanded polytetrafluoroethylene locally in the void areas of the endoluminal stent in its reduced diametric state to a temperature above the crystalline melt point of the 20 polytetrafluoroethylene for a period of time sufficient to monolithically join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene in the void areas. 25
30. A method for making an encapsulated stent-graft, comprising the steps of: a. an endoluminal stent made of a pseudoelastic material and having a pre determined austenite tubular dimensional state at a temperature above the martensite transformation temperature of the shape memory alloy (Ar); 30 b. deforming the endoluminal stent at a temperature above Af, but below Md to reduce the diametric dimension of the endoluminal stent to a diameter suitable for endoluminal delivery thereof, the deformation being -33- WO 99/38455 PCT/US98/08994 performed substantially without plastic deformation of the endoluminal stent; c. concentrically engaging the deformed endoluminal stent in its reduced diametric state about a first layer of longitudinally expanded 5 polytetrafluoroethylene; d. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the deformed endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene; e. applying a circumferential pressure about the first and second layers of 10 longitudinally expanded polytetrafluoroethylene and the endoluminal stent; and f exposing the first and second layers longitudinally expanded polytetrafluoroethylene locally in the void areas of the endoluminal stent in its reduced diametric state to a temperature above the crystalline melt 15 point of the polytetrafluoroethylene for a period of time sufficient to monolithically join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene in the void areas. 20 -34-
AU71759/98A 1998-02-02 1998-05-04 Encapsulated intraluminal stent-graft and methods of making same Expired AU733860B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1998/002361 WO1998033453A2 (en) 1997-02-05 1998-02-02 Radially expandable tubular polytetrafluoroethylene grafts and method of making same
WOUS98/02361 1998-02-02
PCT/US1998/008994 WO1999038455A1 (en) 1998-02-02 1998-05-04 Encapsulated intraluminal stent-graft and methods of making same

Publications (2)

Publication Number Publication Date
AU7175998A true AU7175998A (en) 1999-08-16
AU733860B2 AU733860B2 (en) 2001-05-31

Family

ID=22266351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71759/98A Expired AU733860B2 (en) 1998-02-02 1998-05-04 Encapsulated intraluminal stent-graft and methods of making same

Country Status (5)

Country Link
EP (1) EP1054646A1 (en)
JP (1) JP4057238B2 (en)
AU (1) AU733860B2 (en)
CA (1) CA2318829C (en)
WO (1) WO1999038455A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395019B2 (en) 1998-02-09 2002-05-28 Trivascular, Inc. Endovascular graft
US6613082B2 (en) 2000-03-13 2003-09-02 Jun Yang Stent having cover with drug delivery capability
US6379382B1 (en) 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
US7270675B2 (en) 2002-05-10 2007-09-18 Cordis Corporation Method of forming a tubular membrane on a structural frame
US7485141B2 (en) 2002-05-10 2009-02-03 Cordis Corporation Method of placing a tubular membrane on a structural frame
US8088158B2 (en) 2002-12-20 2012-01-03 Boston Scientific Scimed, Inc. Radiopaque ePTFE medical devices
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
US8313524B2 (en) 2004-08-31 2012-11-20 C. R. Bard, Inc. Self-sealing PTFE graft with kink resistance
WO2007004076A2 (en) 2005-05-09 2007-01-11 Angiomed Gmbh & Co. Medizintechnik Kg Implant delevery device
EP1945138A4 (en) 2005-11-09 2010-02-10 Bard Inc C R Grafts and stent grafts having a radiopaque marker
US8425584B2 (en) * 2006-04-21 2013-04-23 W. L. Gore & Associates, Inc. Expandable covered stent with wide range of wrinkle-free deployed diameters
US8721704B2 (en) 2006-04-21 2014-05-13 W. L. Gore & Associates, Inc. Expandable stent with wrinkle-free elastomeric cover
FR2904560B1 (en) * 2006-08-07 2009-10-23 Patrice Bergeron ENDOPROTHESIS AND SYSTEM COMPRISING SUCH ENDOPROTHESIS
CA2701096A1 (en) 2007-10-04 2009-04-09 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
JP5657943B2 (en) * 2010-08-02 2015-01-21 株式会社カネカ Manufacturing method of stent delivery catheter
US9775933B2 (en) * 2012-03-02 2017-10-03 W. L. Gore & Associates, Inc. Biocompatible surfaces and devices incorporating such surfaces
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
CN108814768B (en) * 2013-07-22 2020-08-07 阿特利姆医疗公司 Implants having expandable regions and methods of making and using the same
WO2022030085A1 (en) * 2020-08-03 2022-02-10 株式会社カネカ Tubular medical instrument transfer device and method for manufacturing tubular medical instrument transfer device
AU2021429970A1 (en) * 2021-02-25 2023-09-14 W. L. Gore & Associates, Inc. Geometrically deformable implantable containment devices for retention of biological moieties

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5735892A (en) * 1993-08-18 1998-04-07 W. L. Gore & Associates, Inc. Intraluminal stent graft
DE69518275T3 (en) * 1994-06-08 2007-10-18 CardioVascular Concepts, Inc., Portola Valley Blood vessel graft
EP0767684B1 (en) * 1994-06-27 2005-05-25 Bard Peripheral Vascular, Inc. Radially expandable polytetrafluoroethylene and expandable endovascular stents formed therewith
EP0814729B1 (en) * 1995-03-10 2000-08-09 Impra, Inc. Endoluminal encapsulated stent and methods of manufacture
CA2229537A1 (en) * 1995-08-24 1997-03-06 Impra, Inc. Covered endoluminal stent and method of assembly
ES2293653T3 (en) * 1995-12-14 2008-03-16 Gore Enterprise Holdings, Inc. REINFORCEMENT OF STENT RESISTANT TO RETORCIMIENTO.

Also Published As

Publication number Publication date
CA2318829C (en) 2007-11-13
JP2002501779A (en) 2002-01-22
AU733860B2 (en) 2001-05-31
EP1054646A1 (en) 2000-11-29
JP4057238B2 (en) 2008-03-05
CA2318829A1 (en) 1999-08-05
WO1999038455A1 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
US6451047B2 (en) Encapsulated intraluminal stent-graft and methods of making same
CA2318829C (en) Encapsulated intraluminal stent-graft and methods of making same
EP1041941B2 (en) Supported graft
JP4728349B2 (en) Manufacturing method of ePTFE and structure including ePTFE such as vascular graft
EP1202682A1 (en) Intraluminal stent graft
JP2008526317A5 (en)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: BARD PERIPHERAL VASCULAR, INC.

Free format text: FORMER NAME WAS: IMPRA, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired